Clinical implications
AF is the most common cardiac arrhythmia affecting over 33 million people worldwide, and the incidence of AF is increasing.17 Patients with AF have an increased risk of stroke, heart failure, cardiovascular hospitalization, and mortality.18 Although catheter ablation can effectively treat some patients, the long-term success rate is low, and the recurrence rate is high and there has been no progress in the development of new antiarrhythmic drugs in recent years..19,20 Our present study found that the expression of KCa3.1 was heterogeneous in different parts of the rabbits atrium. The high expression of KCa3.1 in the PVs and SVC is an important mechanism for triggering activity. Inhibition of KCa3.1 significantly suppressed triggering activity. Taken together, our findings provide an experimental basis for clinical AF treatment and drug development.